Transcript: Which HIV Meds Cause Lipoatrophy?

Transcript: Beyond Condoms: Medical Approaches For Prevention

Transcript: Simple Test Eliminates Abacavir Risk

Transcript: Are We Starting Treatment Early Enough?

Transcript: The Latest on Lipo: Advances & Setbacks

Prezista Superior to Kaletra for Treatment-Experienced Patients
Preliminary results from a major clinical trial have demonstrated that Prezista plus Norvir is more effective than Kaletra in treatment-experienced HIV-positive patients.

NNRTI Etravirine Effective for Treatment-Experienced Patients
Studies reviewed at the fourth IAS Conference in Sydney indicate that Tibotec's NNRTI etravirine, combined with the company's PI Prezista, is safe and effective for treatment-experienced HIV-positive patients.

PRO 140 Shows Promise in Single-Dose Study
Researchers have reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor.

Activist Urges China to Lift Its HIV Travel Ban

California: Two AIDS Groups Merge to Overcome Economic Woes

Researchers Enlist Dark-Haired Volunteers for PrEP Study

Rochester Researchers Explore Possible HIV-Associated Hearing Loss
Specialists in HIV and in hearing at the University of Rochester Medical Center in New York State and are gearing up to conduct what they believe is the first large study to examine potential connections between HIV infection and hearing loss. The study, announced in a November 5 press release, is being supported by a $1.9 million grant from the National Institute on Deafness and Other Communication Disorders.

No Heart Rhythm Problem With 25 mg of Rilpivirine
People taking a 25 mg once-daily dose of rilpivirine (TMC278) had no signs of trouble with their heart rhythm, according to a study presented November 1 at the Infectious Disease Society of America conference in Philadelphia and reported by the National AIDS Treatment Advocacy Project (NATAP). These study results are encouraging, as this is the dose being explored for use in people starting HIV treatment for the first time. 

Many HIV-Positive Swiss MSM Have Chlamydia—and Don’t Know It
More than 10 percent of Swiss HIV-positive men who have sex with men (MSM) were infected with rectal Chlamydia trachomatis—many without knowing it—according to a study published November 15 in Clinical Infectious Diseases and reported by aidsmap.com.

Coffee Lowers Risk of Hep C Progression
People with hepatitis C virus (HCV) who drank three or more cups of coffee per day had a 53 percent lower risk of liver disease progression than those who didn’t drink coffee, according to a study published in the November issue of Hepatology and reported by ScienceDaily. The people in the study were infected only with HCV and not with both HIV and HCV.

Common Support Schemes Failed to Increase Adherence Over the Long-Term
Programs developed to support the correct and regular dosing of antiretroviral (ARV) therapy among people living with HIV may not be as effective as experts might have hoped, according to a sobering study published online October 28 in the Journal of Acquired Immune Deficiency Syndromes. Neither peer support or pager reminders significantly boosted adherence rates in a University of Washington study conducted in Seattle.  

Lower Norvir Boosting Dose Possible
Three protease inhibitors (PIs)—Invirase (saquinavir), Prezista (darunavir) and Lexiva (fosamprenavir)—might require a lower dose of Norvir (ritonavir) to boost their blood levels than is currently recommended, according to a study published November 13 in AIDS

Therapeutic Vaccines: Steady Wins the Race
Recent news of modest success with a preventive HIV vaccine has led some to wonder whether we’ve moved any closer to a compound that can train the immune system to better control the virus—a therapeutic vaccine. AIDSmeds talked to two HIV vaccine experts to find out where we are now and where we’re going.